Pre-made Sofituzumab benchmark antibody ( Whole mAb ADC, anti-MUC16 therapeutic antibody, Anti-CA125 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Sofituzumab biosimilar, Whole mAb ADC, Anti-MUC16 Antibody: Anti-CA125 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sofituzumab vedotin (INN; development code DMUC5754A) is a monoclonal antibody designed for the treatment of ovarian cancer. This drug was developed by Genentech/Roche.
| Products Name (INN Index) | Pre-Made Sofituzumab biosimilar, Whole mAb ADC, Anti-MUC16 Antibody: Anti-CA125 therapeutic antibody |
|---|---|
| INN Name | Sofituzumab |
| Target | MUC16 |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Genentech |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Fallopian tube cancer,Ovarian cancer,Pancreatic cancer,Peritoneal cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MUC16 |
| Package |
